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Background: Telomerase activity (TA) is considered as the biomarker for cardiovascular
aging and cardiovascular diseases (CVDs). Recent studies suggest a link between
statins and telomere biology that may be explained by anti-inflammatory actions of
statins and their positive effect on TA. Until now, this effect has not been investigated
in prospective randomized studies. We hypothesized that 12 months of atorvastatin
therapy increased TA in peripheral blood mononuclear cells.
Methods: In a randomized, placebo-controlled study 100 hypercholesterolemic
patients, aged 35–75 years, free of known CVDs and diabetes mellitus type 2 received
20 mg of atorvastatin daily or placebo for 12 months. TA was measured by quantitative
polymerase chain reaction.
Results: At study end, 82 patients had sufficient peripheral blood mononuclear cells
needed for longitudinal analysis. TA expressed as natural logarithms changed from
0.46 ± 0.05 to 0.68 ± 0.06 (p = 0.004) in the atorvastatin group and from 0.67 ± 0.06
to 0.60 ± 0.07 (p = 0.477) in the control group. In multiple regression analysis,
atorvastatin therapy was the only independent predictor (p = 0.05) of the changes in
TA independently of markers of chronic inflammation and oxidative stress. Atorvastatin
therapy was associated with increases in interleukin-6 within the normal range and a
tendency toward reduction in blood urea.
Conclusion: These initial observations suggest atorvastatin can act as telomerase
activator and potentially as effective geroprotector.
Trial registration: The trial was registered in ISRCTN registry ISRCTN55050065.
Keywords: telomerase activity, chronic inflammation, blood urea, statins
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INTRODUCTION
It is known that statins prolong lifespan in lower organisms
(Spindler et al., 2012) and reduce total human mortality, even
in people who have normal lipid levels; statins are the first-line
drugs in the primary and secondary prevention of cardiovascular
diseases (CVDs; Taylor et al., 2011). In many respects, this may
be explained by the pleiotropic effects of statins, i.e., which
are not associated with lipid-lowering effects. Pleiotropic effects
are observed in various cell types including endothelial cells,
leukocytes, fibroblasts, and smooth muscle cells (Olivieri et al.,
2012). The most widely studied pleiotropic effects of statins
are: decreasing of the vascular wall inflammation (Bu et al.,
2011), reduced production of intracellular reactive oxygen species
(Hong et al., 2006), increasing of the nitric oxide bioavailability
(Ni et al., 2001), reduction of platelet aggregation (Casani et al.,
2005), angiogenesis stimulation (Shen et al., 2011), immune
response modulation (Kwak et al., 2000), and reduction of
erythrocyte membranes cholesterol concentration—a marker of
clinical instability in patients with coronary heart disease (CHD;
Tziakas et al., 2009). The most recently revealed pleiotropic
effects of atorvastatin include the prevention of cell aging, the
reduction of apoptosis in endothelial progenitor cells, mature
endothelial cells, and smooth muscle cells (Assmus et al., 2003;
Satoh et al., 2009). Telomere shortening plays a major role in the
development of replicative cellular senescence. Telomeres are the
regions of repetitive TTAGGG nucleotide sequences at the ends
of the linear chromosomal DNA. Shelterin complex, represented
by several proteins (TRF1, TRF2, POT1, TIN2, TPP1, Rap1),
forms a protective “cap” at the 3′-end of telomere. It protects
the linear chromosome ends from degradation and fusion, and
is involved in the maintenance of genome stability. Each round
of chromosomal replication leads to the telomere shortening.
Once the length of telomere DNA becomes extremely short,
cell aging occurs, i.e., the cells inability to further divide and to
repair damaged DNA (while maintaining the metabolic activity).
Telomere dysfunction with similar effects is developing, while
removing “shelterin protection.” The increase in the population
of old (senescent) cells in tissues reduces the functional capacity
of these tissues and the phenotype of aging begins to form.
The current data suggest a connection between the processes
of telomere shortening, vascular aging, and the development of
CVD (Rotar et al., 2012).
Telomerase, which completes telomere DNA repeats,
maintains telomere length (TL). Telomerase is a
ribonucleoprotein complex that belongs to the DNA-dependent
RNA polymerases family (reverse transcriptases). It includes
telomerase reverse transcriptase (TERT) and telomerase RNA
component (TERC) used as a template for the telomeric DNA
synthesis. High telomerase activity (TA) is observed in embryonic
stem cells, cancer cells, and human germ cells throughout human
life. In cells, in which differentiation is completed, TA decreases
Abbreviations: ApoA1, apolipoprotein A1; ApoB, apolipoprotein B; ApoE,
apolipoprotein E; CHD, coronary heart disease; CRP, C-reactive protein; CVD,
cardiovascular disease; FBG, fibrinogen; IL-6, interleukin-6; TA, telomerase
activity; TERC, telomerase RNA component; TERT, telomerase reverse
transcriptase; TL, telomere length.
and the cells’ telomeres begin to shorten with each division, i.e.,
each division of these cells leads to aging. This is the typical
pattern for most eukaryotic cells. However, there are rare but
important exceptions. TA is detected in “mortal” cells such as
macrophages and leukocytes.
One of the newly discovered pleiotropic effects of statins is
their ability to prevent telomere shortening, both directly and
by maintaining the shelterin complex stability and by increasing
TA (Brouilette et al., 2007; Satoh et al., 2009; Saliques et al.,
2011; Boccardi et al., 2013a). However, there are very few clinical
studies which have evaluated the effects of statin therapy on TA.
The main goal of our work was to study the effect of atorvastatin
on the TA in patients with hypercholesterolemia and without
clinical signs of CVD.
Moreover, considering the well-known anti-inflammatory
and antioxidant properties of statins, it seems important to
assess their impact on major markers of inflammation such as
interleukin-6 (IL-6) and the “new” marker of oxidative stress—
blood urea (D’Apolito et al., 2015). Our interest in this area was
heightened by the recently published data on the controversial
effects of IL-6 in the basic cellular processes; specifically, not only
the proinflammatory effects of IL-6 but also its anti-apoptotic
and anti-inflammatory properties (Scheller et al., 2011) and its
essential role in TA regulation (Yamagiwa et al., 2006).
MATERIALS AND METHODS
Patients who had passed a preventive outpatient examination in
the National Research Center for Preventive Medicine, Moscow,
Russia, in 2012–2013 were included in the study. The inclusion
criteria were as follows: diagnosed with hypercholesterolemia:
low-density lipoprotein cholesterol (LDL-C) ≥160 mg/dL
(4.16 mmol/L) in the presence of 0–1 CVD risk factors and LDL-
C ≥ 130 mg/dL (3.38 mmol/L) in the presence of two or more
CVD risk factors (Grundy et al., 2004); and the absence of any
lipid-lowering therapy at the time of inclusion.
Criteria for exclusion from the study were as follows:
any chronic somatic diseases, including CVD associated with
atherosclerosis, grade 3 hypertension, chronic heart failure
[New York Heart Association (NYHA) functional classification
III–IV], chronic kidney disease (glomerular filtration rate
<60 mL/min/1.73m2), liver disease, type 2 diabetes mellitus,
acute and chronic inflammatory diseases, cancer, pregnancy,
lactation, and refusal to participate in the study. All patients
signed a legal informed consent form to participate in the study.
The Independent Ethics Committee of the National Research
Center for Preventive Medicine, Moscow, Russia approved the
study protocol.
Patients visited the clinic to undergo the study protocol
examinations from 08:00 to 09:00 AM after a 12-h period of
fasting. Blood pressure was measured by using brachial cuff
(HEM-7200 M3, Omron Healthcare, Kyoto, Japan) on the right
hand in a sitting position three times for 2-min intervals after
a 10-min rest; the average of the three measurements was
used for analysis. Hypertension was diagnosed when BP was
≥140/90 mm Hg.
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The concentrations of total cholesterol, triglycerides,
apolipoprotein A1 (ApoA1), and apolipoprotein B (ApoB)
were determined by the biochemical analyzer SAPPHIRE-
400 using enzyme kits. The concentration of high-density
lipoprotein cholesterol was determined by using the same
analyzer in the supernatant after precipitation of serum ApoB-
containing lipoproteins. The level of LDL-C was calculated by
the Friedewald equation (when triglycerides level was no higher
than 4.5 mmol/L).The level of the blood urea was measured by
enzymatic photometric method on SAPPHIRE-400 analyzer.
The C-reactive protein (CRP) concentration (reference
values 0–5 mg/L) and fibrinogen (FBG) concentration
(reference values 2–4 g/L) were measured by a highly sensitive
immunoturbidimetric method using carboxylated polystyrene
particles on a biochemical analyzer, “Sapphire.”
IL-6 level (reference values of 0–10 pg/mL) was measured
by using the immunoenzyme method. Malondialdehyde
was measured by high-performance liquid chromatography
(reference values of 2.2–4.8 mmol/L).
TA was measured using the method described by Kim
et al. (1994). The analysis of cellular extract from monocyte
fraction of white blood cells (erythrocytes prevents impurity
analysis) containing 2 µg of total protein was performed.
The cells, derived from the monocytic ring on Ficoll density
gradient and washed with phosphate buffered saline (PBS),
were re-suspended in lytic buffer [10 mM Tris–HCl and
10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
(HEPES)-KOH, pH 7.5, 1.0 mM MgCl2, 1 mM ethylene
glycol-bis(β-aminoethyl ether)-N,N,N′,N′-tetraacetic acid
(EGTA), 5 mM β-mercaptoethanol, 5% glycerol, 0.5% 3-
[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate
(CHAPS), 0.1 mM phenylmethylsulfonyl fluoride (PMSF)].
The cells were incubated for 30 min on ice, centrifuged for
10 min at 4◦C for 15,000 g, and the supernatant solution
was collected. The extract was aliquoted and frozen in liquid
nitrogen. The telomerase polymerase reaction was carried out
with 24 µL of 1.2x master mix [1x mix contains 1x telomere
repeat amplification protocol (TRAP)-buffer (1x TRAP-buffer:
20 mM HEPES-KOH pH 8.3, 1.5 mM MgCl2, 63 mM KCl,
1 mM EGTA, 0.1 mg/mL bovine serum albumin (BSA), 0.005%
v/v Tween-20), 20 pM of dNTP, 10 pmol of oligonucleotide TS
(AATCCGTCGAGCAGAGTT), and 4 µL monocyte or control
extract]. The reaction mixture was incubated for 30 min at
25◦C. The products were amplified by polymerase chain reaction
(PCR) in real time. Thereafter, 1.5 U of Taq-DNA polymerase
(Helicon), 10 pmol of oligonucleotide oligonucleotide 5′-
GCGCGGCTTACCCTTACCCTTACCCTAACC-3′ (ACX)
(CGCGGCTTACCCTTACCCTTACCCTTACC), and Sybr
Green I to 0.2x final concentration in the mixture were added
in ice (together 2 µL volume). Real-time PCR was carried out
on the device CFX-96 for 35 s at 94◦C, 35 s at 50◦C, and 90 s
at 72◦C (30 cycles of thermal cycler Mastercycler (Bio-Rad).
As a calibration curve, a series of dilutions of cell extracts of
telomerase-positive HEK293T cell line (HEK) (15 cells activity
was set as 1) and TSR8 [sequence identical to the TS primer
extended with eight telomeric repeats AG (GGTTAG)7] has been
used.
Statistical Analysis
Data processing and analysis were carried out by using the
statistical system SAS 9.1 (SAS Institute, Cary, NC, USA). The
results are presented in percentages for qualitative variables
and as mean ± standard error of the mean for quantitative
variables. Comparison of the signs prevalence in groups was
performed by using Fisher’s exact two-tailed test. According
to the distribution character, the Mann–Whitney U-test or
Student’s t-test were used for comparing patient groups. The
non-parametric Wilcoxon rank-sum test was used in cases
when the assumptions, allowing to proceed the paired t-test for
dependent samples, had not been accomplished. Spearman’s rank
correlation coefficient was calculated for statistical description
of the relationship between different parameters. Evaluation of
the various factors contributing to the magnitude of TA was
performed using stepwise regression analysis. Differences were
considered statistically significant when p< 0.05.
Study Design
A total of 100 patients aged 35–75 years who met the inclusion
and exclusion criteria were included. They were randomized 1:1
to the group treated with atorvastatin 20 mg/day and a control
group of patients who did not receive atorvastatin.
All patients were given recommendations for lifestyle
modifications (diet and physical activity). After 2 months of
atorvastatin treatment, its safety was monitored. At the end of
the observation period (12 months) patients were re-examined
for parameters included in the study.
RESULTS
At baseline, the groups did not differ in age, gender, smoking
status, level of blood pressure, lipid profile, and other biochemical
parameters. Forty-four participants adhered to treatment with
atorvastatin; in the group of patients who were not administered
atorvastatin, 38 people were re-examined.
The clinical characteristics of the patients in both groups
at baseline and after 12 months of treatment are shown in
the Table 1. In the atorvastatin group, by the end of the year
statistically significant reductions in total cholesterol level had
been shown (from 6.6 ± 1.1 to 5.8 ± 1.5 mmol/L, p = 0.005), as
well as reductions in LDL-C (from 4.5± 1.0 to 3.9± 1.4 mmol/L),
triglycerides (1.9 ± 1.1 to 1.5 ± 0.7 mmol/L, p = 0.045), ApoB
(130.3 ± 36.2 to 96.2 ± 27.7 mg/dL, p < 0.001), and increases
in ApoA1 (from 173.4 ± 28.8 to 195.1 ± 41.9, p = 0.006.).
Systolic blood pressure and diastolic blood pressure rates had not
changed.
The main aim of our study was to assess the influence of
atorvastatin treatment on TA. Treatment with atorvastatin for
1 year resulted in a statistically significant increase of TA (from
0.46 ± 0.05 to 0.68 ± 0.06, p = 0.004) in contrast to the control
group, where TA did not change significantly (from 0.67 ± 0.06
to 0.60 ± 0.07, p = 0.477). This positive atorvastatin effect on
TA was associated with a statistically significant increase in IL-
6 and a marginally significant decrease in blood urea. However,
there were no statistically significant dynamics of CRP, FBG, or
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TABLE 1 | Characteristics of patients with hypercholesterolemia
randomized to the atorvastatin and control groups.
Atorvastatin
(n = 44)
Without
treatment (n = 38)
p1
Age, years, M ± m Baseline 59.2 ± 1.2 51.4 ± 1.2 <0.05
Male, % (n) Baseline 34.1 (15) 32.1 (12) 0.848
Smokers, % (n) Baseline 25 (11) 18.4 (7) 0.470
SBP, mm Hg, Baseline 128.8 ± 2.3 127.5 ± 2.3 0.644
M ± m 12-months 132.5 ± 2.5 124.9 ± 2.3
p2 0.280 0.434
DBP, mm Hg, Baseline 80.2 ± 1.6 79.4 ± 1.6 0.729
M ± m 12 months 82.0 ± 1.5 79.2 ± 1.5
p2 0.419 0.928
TC mmol/L, Baseline 6.6 ± 0.2 6.1 ± 0.1 0.03
M ± m 12 months 5.8 ± 0.2 6.3 ± 0.2
p2 0.005 0.309
LDL-C, mmol/L, Baseline 4.5 ± 0.2 4.4 ± 0.1 0.607
M ± m 12 months 3.9 ± 0.2 4.5 ± 0.2
p2 0.023 0.530
HDL-C, mmol/L, Baseline 1.18 ± 0.05 1.21 ± 0.05 0.699
M ± m 12 months 1.27 ± 0.06 1.29 ± 0.06
p2 0.275 0.310
TG, mmol/L, Baseline 1.9 ± 0.2 1.2 ± 0.1 <0.05
M ± m 12 months 1.5 ± 0.1 1.3 ± 0.1
p2 0.045 0.844
ApoA1, mg/dL, Baseline 173.4 ± 4.3 174.8 ± 4.9 0.819
M ± m 12 months 195.1 ± 6.3 182.8 ± 6.5
p2 0.006 0.334
ApoB, mg/dL, Baseline 130.3 ± 5.5 115.7 ± 2.8 0.027
M ± m 12 months 96.2 ± 4.2 104.7 ± 3.3
p2 <0.001 0.017
ApoA1, apolipoprotein A1; ApoB, apolipoprotein B; DBP, diastolic blood pressure;
HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein
cholesterol; M ± m, mean ± standard error of the mean; p1, p-value for
independent groups; p2, p-value for dependent groups; SBP, systolic blood
pressure; TC, total cholesterol; TG, triglycerides.
Malondialdehyde values (Table 2), although in the atorvastatin
group the decline in the proportion of patients with elevated
levels of FBG from 31.8% (14 subjects) at baseline to 13.8%
(six subjects) after 12 months of treatment (p = 0.043) was
recorded. In the control group, this parameter has not changed.
In order to detect possible determinants of atorvastatin effects
on the dynamics of the TA, we conducted the Spearman’s
correlation analysis of the association of the TA dynamics and
the dynamics of other studied parameters. None of them showed
the correlation with the dynamics of the TA (Table 3).
The independent effect of atorvastatin therapy on the
dynamics of TA was confirmed by multifactor linear regression
analysis (p = 0.05; Table 4). Dynamics of all other studied
parameters did not show an independent association with TA
dynamics.
DISCUSSION
We believe ours to be the first prospective randomized study to
demonstrate a positive effect of atorvastatin therapy on TA.
TABLE 2 | Effects of atorvastatin on the markers of chronic inflammation,
oxidative stress, and telomerase activity.
Atorvastatin
(n = 44)
Without
treatment (n = 38)
p1
CRP, mg/L, Baseline 5.3 ± 0.9 3.3 ± 0.7 0.1
M ± m 12 months 4.5 ± 0.1 3.0 ± 0.1
p2 0.520 0.721
FBG, g/L, Baseline 3.60 ± 0.10 3.26 ± 0.06 0.021
M ± m 12 months 3.51 ± 0.10 3.21 ± 0.07
p2 0.519 0.711
IL-6, pg/mL, Baseline 3.64 ± 0.92 5.93 ± 1.91 0.56
M ± m 12 months 6.73 ± 1.04 8.12 ± 3.21
p2 0.021 0.559
MDA, mcmol/L, Baseline 3.1 ± 0.1 3.0 ± 0.1 0.596
M ± m 12 months 3.3 ± 0.1 3.4 ± 0.2
p2 0.244 0.086
Blood urea, Baseline 6.1 ± 0.2 5.6 ± 0.2 0.139
mmol/L, M ± m 12 months 5.5 ± 0.8 5.3 ± 0.2
p2 0.082 0.37
CRP, C-reactive protein; FBG, fibrinogen; IL-6, interleukin 6; MDA,
malondialdehyde; M ± m, mean ± standard error of the mean; p1, p-value
for independent groups, p2, p-value for dependent groups.
TABLE 3 | Correlation between the telomerase activity dynamics and the
dynamics of the markers of chronic inflammation and oxidative stress.
Indicator r p
1TC, mmol/L 0.09 0.421
1LDL-C, mmol/L 0.21 0.06
1TG, mmol/L –0.05 0.655
1ApoA1, mg/dL 0.09 0.438
1ApoB, g/dL 0.04 0.721
1CRP, mg/dL 0.17 0.126
1FBG, g/L 0.06 0.592
1IL-6, pg/mL 0.01 0.928
1Blood urea, mmol/L 0.13 0.244
Spearman’s correlation coefficients.1 represents dynamics of studied parameters
from baseline to 12 months of atorvastatin therapy; 1ApoA1, apolipoprotein
A1 dynamics; 1ApoB, apolipoprotein B dynamics; 1CRP, C-reactive protein
dynamics; 1FBG, fibrinogen dynamics; 1IL-6, interleukin-6 dynamics; 1LDL-C,
low-density lipoprotein cholesterol dynamics; 1TC, total cholesterol dynamics;
1TG, triglycerides dynamics.
After 1 year of treatment, there was a statistically significant
increase in TA in the atorvastatin group compared with the
control group, where TA had not significantly changed. The
independent impact of statin therapy on the dynamics of TA was
confirmed by multifactor regression analysis. According to the
results of our study, age had no significant effect on TA dynamics
(p = 0.083). But even if we accept this p-value as significant then
we can talk about the negative effect of age on TA dynamics.
Nevertheless in the atorvastatin group, where patients were older,
increase in TA confirms the activating effect of statin therapy
on TA.
It should be noted that there are almost no clinical studies
on the effects of statin therapy on TA. Our data are consistent
with the results demonstrated by Boccardi et al. (2013a)
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TABLE 4 | Results of multifactor linear regression analysis with the
telomerase activity as a dependent variable.
Indicators β ± SE p Model R2
Intercept 0.609 ± 0.405 0.139
Atorvastatin 0.381 ± 0.192 0.05
Age –0.013 ± 0.007 0.083
1CRP 0.008 ± 0.016 0.611
1IL-6 –0.006 ± 0.010 0.559
1FBG –0.091 ± 0.127 0.410
1Blood urea –0.052 ± 0.063 0.407 0.1269
β, regression coefficient; 1Blood urea, blood urea dynamics; 1CRP, C-reactive
protein dynamics; 1FBG, fibrinogen dynamics; 1IL-6, interleukin-6 dynamics; SE,
standard error.
who showed that statin treatment in people older than 65
years had been associated with higher TA, longer telomeres,
and slower telomere shortening, regardless of such factors as
age, sex, smoking status, body mass index, the severity of
inflammation, glucose level, cholesterol level, and blood pressure.
The authors concluded that effects of statin therapy on TL
had been mediated by their influence on the TA. In our
work, the effect of atorvastatin on TL has not been studied,
because the dynamics of TL cannot be evaluated during a
12-month period using our PCR methods. In the available
scientific sources, we have found several experimental and
clinical studies where a positive effect of statin therapy on
TL has been demonstrated. Atorvastatin therapy slows cell
aging and prevents telomere shortening in smooth muscle cells,
regardless of the degree of oxidative stress reduction (Satoh
et al., 2009). Intensive atorvastatin therapy during the year
had prevented telomere shortening in contrast with medium-
intensive pravastatin therapy in endothelial progenitor cells in
patients with CHD (Satoh et al., 2009). Few recent clinical studies
confirm a positive effect of statins on TL (Brouilette et al.,
2007; Saliques et al., 2011). One of the basic hypotheses is the
assumption that statins increase TA. Thus, it can be assumed that
statins may be important modulators of TA.
It should be recognized that one of the limitation of the
study may be considered the fact that we have not studied
the association of TA with apolipoprotein E (ApoE) level and
ApoE genetic variants. The potential role of ApoE gene on lipid
response to statin treatment and longevity has been investigated
by numerous studies (Panza et al., 2007; Zintzaras et al., 2009).
It can be assumed that the polymorphism of ApoE gene may
determine influence of statins on TA. This issue could be the
subject of further research.
Recently, there has been a major focus on finding potential
modulators of TA. In experimental studies gene therapy
(Boccardi and Herbig, 2012), telomerase-specific promoters
(Bernades de Jesus and Blasco, 2012) had been investigated.
Recently, it was demonstrated that TA can be influenced by
stress and lifestyles (Jacobs et al., 2011; Daubenmier et al., 2012;
Lavretsky et al., 2013). Lifestyle intervention, comprising a low-
fat diet, regular physical activity, and psycho-emotional stress
reduction for 3 months, led to a significant TA increase in
mononuclear cells. In another study, it was shown that the
Mediterranean diet also led to an increase in TA (Boccardi
et al., 2013b). The potential to modulate the TA is of great
interest given the importance of telomerase function to cells.
As already mentioned, telomerase maintains TL and prevents
telomere dysfunction. Since the TL in leukocytes reflects TL in
progenitor stem cells, it is these TL and TA that indicate the
functional stem progenitor cell state (Oeseburg et al., 2007) and
therefore the ability of tissues to repair damage, also in the vessel
wall (Boytsov et al., 2013). The relationship between TL and the
ability of tissues to repair damages explains the fact that TL and
TA can be considered as universal markers of biological aging
and aging of the cardiovascular system. This is confirmed by
the results of the following studies. The correlation between the
short TL in leukocytes and high mortality has been revealed
in individuals older than 60 years (Sahin and Depinho, 2010).
The association between TL and the duration of healthy life
but not between the TL and mortality has been shown in a
large cohort study (Njajou et al., 2009). Individuals who had
longer telomeres showed better health profile (fewer age-related
diseases, better cognitive function, and better lipid composition).
The results of several cross-sectional (Satoh et al., 2009; Brouilette
et al., 2003) and longitudinal (Brouilette et al., 2007; Farzaneh-Far
et al., 2008) studies suggest that there is a relationship between
telomere biology and risk of developing and prognosis of CVD.
People with shorter telomeres have higher CHD risk. Telomeres
are shorter in patients with early CHD onset and myocardial
infarction (Brouilette et al., 2007), as well as in patients with
carotid atherosclerosis (Nzietchueng et al., 2011). At the same
time, TA may be an even more sensitive and modifiable marker
of aging and disease than TL. Promising results were obtained
both in experimental and clinical studies. TA increase in vitro
promotes the cells’ lifetime prolongation and the genome stability
(Zhu et al., 2000). TA decrease leads to the telomere shortening,
regardless of chronological age, and is associated with increased
CVD risk (Serrano and Andres, 2004). In healthy women, TA not
TL was associated with the main cardiovascular risk factors (Epel
et al., 2010).
Telomerase plays an important role in maintaining the
normal functioning of the mitochondria, where it can be found
besides the nucleus and cytoplasm. This localization under stress
conditions may exert a protective effect on mitochondria as well
as on the whole cell. Observations in some laboratories showed
that telomerase reduced mitochondrial reactive oxygen species
production and protected the mitochondrial DNA from damages
(Pykhtina et al., 2014).
The second important findings of this study is the observed
increase in the level of IL-6 observed during statin therapy.
This result may seem surprising, since anti-inflammatory effects
of statins are well known, and IL-6 has long been considered
a pro-inflammatory cytokine associated with the risk of many
age-related diseases, including CVD, and death caused by
cardiovascular disorders (Ridker et al., 2000). Moreover, in
one study, it has been demonstrated that atorvastatin therapy
for 9 months resulted in a decrease of IL-6 (Nawawi et al.,
2003). Recently, it was revealed that IL-6 might have both
inflammatory and anti-inflammatory effects depending on the
type of activated intracellular signaling pathway. The “classical”
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signaling pathway activation occurs during the joining of
IL-6 with the receptor connected with the cell membrane;
however, very few cells are capable of expressing the receptors
associated with the membrane. Among them are immune
cells, hepatocytes, and myocytes. As a result, anti-inflammatory
reaction is activated, epithelial cell regeneration after injury
occurs, and metabolism in the liver is monitored. Activation
of the “trans-signaling” pathway results in binding of IL-6
with the soluble form of the receptor. Vascular endothelium,
osteoclasts, and synovial fibroblasts become targets for IL-6.
IL-6 pro-inflammatory potential is realized. Such a script can
be observed in chronic inflammatory diseases such as Crohn’s
disease and rheumatoid arthritis. In this case, STAT3 (signal
transducer and activator of transcription 3) mediates this process.
STAT3 moves to the nucleus and enhances transcription of
many genes, including encoding the formation of acute phase
proteins. It can be assumed that the increased expression of
IL-6 in healthy individuals is intended to protect the organism
from harmful external effects, to restore homeostasis, and to
normalize metabolism. This may be confirmed by the results of
the work, where the influence of such physiological stimulus as
exercise resulted in increased IL-6 levels and improved tissue
insulin sensitivity (Pal et al., 2014). It can be assumed that
statin therapy leads to the activation of similar mechanisms.
It should again be emphasized that in our study, we focused
on IL-6 increase in the framework of reference values. In a
pathological environment, when IL-6 synthesis regulation is
dramatically impaired, cytokine levels increase significantly and
chronic inflammation evolves. Increased expression of IL-6
may play a role in the telomerase activation. The possibility
of telomerase activation influenced by inflammatory stimuli
has been demonstrated in the study by Gizard et al. (2011),
which demonstrated that this relationship is realized by the
interaction of nuclear factor-kB with the TERT gene promoter.
The inhibition of nuclear factor-kB resulted in the cessation
of TERT expression. The absence of a statistically significant
relationship between the TA dynamics and the IL-6 dynamics
in our study may be due to insufficient statistical power of the
selection.
We consider that the third important finding of our
work is the decline in blood urea level observed during the
statin therapy. Our data are consistent with the results of
preclinical work, including the study by Maheshwari et al.
(2013) which demonstrated the nephroprotective effect of
statins, namely the improvement of renal function and reduced
urea levels in rats with cisplatin-induced renal dysfunction.
According to recent data, urea is recognized as the marker
of oxidative stress (D’Apolito et al., 2015). Due to the
induction of reactive oxygen species formation in the endothelial
cells, mitochondrial urea causes a pro-inflammatory state in
endothelial cells, enhancing the formation of advanced glycation
end products, activating mechanisms of cellular damage, and
causing endoplasmic reticulum stress. The effects of urea
are generally similar to the effects of hyperglycemia. Thus,
our work, by studying the blood urea as a new marker of
oxidative stress, has confirmed the antioxidant properties of
atorvastatin.
CONCLUSION
The success of recent studies in the field of cellular and vascular
aging allows us to identify a clear direction of development for a
translational approach to age-related disease prevention. An issue
of great interest is the regulation of TA, which has the ability
not only to maintain TL, but also to preserve the function of
mitochondria and to obtain a beneficial antioxidant and anti-
apoptotic effect. Telomerase may play the most important role
in the maintenance of optimal cells and tissues function. The
preliminary observations may provide grounds to use statins as
telomerase activators and effective geroprotectors. In order to
reach firmer conclusions, however, we need further extensive
studies which would show whether statins could be considered
as targeted agents of the prevention of cellular and vascular
aging.
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